Journal Article
. 2016 Aug; 7:12335.
doi: 10.1038/ncomms12335.

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Lewis Zhichang Shi 1 Tihui Fu 1 Baoxiang Guan 1 Jianfeng Chen 1 Jorge M Blando 2 James P Allison 2 Liangwen Xiong 1 Sumit K Subudhi 1 Jianjun Gao 1 Padmanee Sharma 1 
  • PMID: 27498556
  •     54 References
  •     43 citations


Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in different types of cancer. However, the underlying mechanisms remain elusive. Here, combining detailed analysis of human tumour samples with preclinical tumour models, we report that concomitant blockade of CTLA-4 and PD-1 improves anti-tumour immune responses and synergistically eradicates tumour. Mechanistically, combination therapy relies on the interdependence between IL-7 and IFN-γ signalling in T cells, as lack of either pathway abrogates the immune-boosting and therapeutic effects of combination therapy. Combination treatment increases IL-7Rα expression on tumour-infiltrating T cells in an IFN-γ/IFN-γR signalling-dependent manner, which may serve as a potential biomarker for clinical trials with immune checkpoint blockade. Our data suggest that combining immune checkpoint blockade with IL-7 signalling could be an effective modality to improve immunotherapeutic efficacy. Taken together, we conclude that combination therapy potently reverses immunosuppression and eradicates tumours via an intricate interplay between IFN-γ/IFN-γR and IL-7/IL-7R pathways.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Antoni Ribas, Begoña Comin-Anduix, +9 authors, Alistair J Cochran.
Clin Cancer Res, 2009 Jan 02; 15(1). PMID: 19118070
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Differential in vivo persistence of two subsets of memory phenotype CD8 T cells defined by CD44 and CD122 expression levels.
Thierry Walzer, Christophe Arpin, Laurent Beloeil, Jacqueline Marvel.
J Immunol, 2002 Mar 09; 168(6). PMID: 11884436
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y Ishida, Y Agata, K Shibahara, T Honjo.
EMBO J, 1992 Nov 01; 11(11). PMID: 1396582    Free PMC article.
Highly Cited.
IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection.
Sara L Colpitts, Nicole M Dalton, Phillip Scott.
J Immunol, 2009 Apr 22; 182(9). PMID: 19380817    Free PMC article.
Homeostasis of naive and memory T cells.
Charles D Surh, Jonathan Sprent.
Immunity, 2008 Dec 23; 29(6). PMID: 19100699
Highly Cited. Review.
IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer.
Asa Andersson, Seok-Chul Yang, +7 authors, Sherven Sharma.
J Immunol, 2009 May 21; 182(11). PMID: 19454692
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.
Marc Pellegrini, Thomas Calzascia, +12 authors, Tak W Mak.
Nat Med, 2009 Apr 28; 15(5). PMID: 19396174
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
Claude Sportès, Frances T Hakim, +17 authors, Crystal L Mackall.
J Exp Med, 2008 Jun 25; 205(7). PMID: 18573906    Free PMC article.
Highly Cited.
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Curr Opin Immunol, 2012 Jan 13; 24(2). PMID: 22236695    Free PMC article.
Highly Cited. Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.
C Bryce Johnson, Brian P Riesenberg, +7 authors, Mark P Rubinstein.
Cancer Immunol Res, 2015 Aug 25; 3(12). PMID: 26297711    Free PMC article.
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Sara M Mangsbo, Linda C Sandin, +3 authors, Thomas H Tötterman.
J Immunother, 2010 May 07; 33(3). PMID: 20445343
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Anran Wang, Smita Chandran, +11 authors, Udai S Kammula.
Sci Transl Med, 2012 Aug 31; 4(149). PMID: 22932225    Free PMC article.
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).
Tyler R Simpson, Sergio A Quezada, James P Allison.
Curr Opin Immunol, 2010 Feb 02; 22(3). PMID: 20116985
IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells.
Anne-Kristin Heninger, Anke Theil, +5 authors, Paolo Monti.
J Immunol, 2012 Nov 07; 189(12). PMID: 23129754
Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent on IFN-gamma signaling during acute malaria.
Nikolai N Belyaev, Douglas E Brown, +5 authors, Alexandre J Potocnik.
Nat Immunol, 2010 May 01; 11(6). PMID: 20431620
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Bradley C Carthon, Jedd D Wolchok, +8 authors, Padmanee Sharma.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460488    Free PMC article.
Highly Cited.
The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison.
Science, 2015 Apr 04; 348(6230). PMID: 25838373
Highly Cited. Review.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Differential tumor surveillance by natural killer (NK) and NKT cells.
M J Smyth, K Y Thia, +7 authors, D I Godfrey.
J Exp Med, 2000 Feb 24; 191(4). PMID: 10684858    Free PMC article.
Highly Cited.
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
Serena K Perna, Daria Pagliara, +4 authors, Gianpietro Dotti.
Clin Cancer Res, 2013 Oct 08; 20(1). PMID: 24097874    Free PMC article.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate gene expression and production of interleukin-7 in human intestinal epithelial cells.
Shigeru Oshima, Tetsuya Nakamura, +10 authors, Mamoru Watanabe.
Mol Cell Biol, 2004 Jul 01; 24(14). PMID: 15226432    Free PMC article.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy, Karen M Kaluza, Gordon J Freeman, George Coukos.
Cancer Res, 2013 May 02; 73(12). PMID: 23633484    Free PMC article.
Highly Cited.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Inhibitory role of the transcription repressor Gfi1 in the generation of thymus-derived regulatory T cells.
Lewis Zhichang Shi, Nishan S Kalupahana, +4 authors, Hongbo Chi.
Proc Natl Acad Sci U S A, 2013 Aug 07; 110(34). PMID: 23918371    Free PMC article.
Role of NK cells in tumour growth and metastasis in beige mice.
J E Talmadge, K M Meyers, D J Prieur, J R Starkey.
Nature, 1980 Apr 17; 284(5757). PMID: 7366733
Highly Cited.
Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro.
I C Summerhayes, L M Franks.
J Natl Cancer Inst, 1979 Apr 01; 62(4). PMID: 107359
The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
Michael A O'Donnell, Yi Luo, +3 authors, Steven K Clinton.
J Urol, 2004 Feb 10; 171(3). PMID: 14767344
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
Weiyi Peng, Chengwen Liu, +8 authors, Patrick Hwu.
Cancer Res, 2012 Aug 24; 72(20). PMID: 22915761    Free PMC article.
Highly Cited.
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992292    Free PMC article.
Highly Cited.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Thomas Powles, Joseph Paul Eder, +12 authors, Nicholas J Vogelzang.
Nature, 2014 Nov 28; 515(7528). PMID: 25428503
Highly Cited.
Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.
Susan M Kaech, Joyce T Tan, +3 authors, Rafi Ahmed.
Nat Immunol, 2003 Nov 20; 4(12). PMID: 14625547
Highly Cited.
Mouse CD1-specific NK1 T cells: development, specificity, and function.
A Bendelac, M N Rivera, S H Park, J H Roark.
Annu Rev Immunol, 1997 Jan 01; 15. PMID: 9143699
Highly Cited. Review.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, +22 authors, Andy J Minn.
Nature, 2015 Mar 11; 520(7547). PMID: 25754329    Free PMC article.
Highly Cited.
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
M T Lotze, E A Grimm, +2 authors, S A Rosenberg.
Cancer Res, 1981 Nov 01; 41(11 Pt 1). PMID: 6975652
Highly Cited.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Interleukin 7 regulates the survival and generation of memory CD4 cells.
Robyn M Kondrack, Judith Harbertson, +3 authors, Linda M Bradley.
J Exp Med, 2003 Dec 10; 198(12). PMID: 14662907    Free PMC article.
Highly Cited.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
Steven A Rosenberg, Claude Sportès, +10 authors, Ronald E Gress.
J Immunother, 2006 May 16; 29(3). PMID: 16699374    Free PMC article.
Highly Cited.
Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.
Angelica Loskog, Helena Dzojic, +4 authors, Thomas H Totterman.
J Immunol, 2004 May 22; 172(11). PMID: 15153545
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
V Shankaran, H Ikeda, +4 authors, R D Schreiber.
Nature, 2001 Apr 27; 410(6832). PMID: 11323675
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
Lieping Chen, Xue Han.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325035    Free PMC article.
Highly Cited. Review.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, +13 authors, Padmanee Sharma.
Cell, 2016 Sep 27; 167(2). PMID: 27667683    Free PMC article.
Highly Cited.
ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line.
Kazem Zibara, Asad Zeidan, +3 authors, Nabil El-Zein.
J Cell Commun Signal, 2016 Nov 14; 11(1). PMID: 27838900    Free PMC article.
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.
Paul A Beavis, Melissa A Henderson, +15 authors, Phillip K Darcy.
J Clin Invest, 2017 Feb 07; 127(3). PMID: 28165340    Free PMC article.
Highly Cited.
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Jianjun Gao, John F Ward, +16 authors, Padmanee Sharma.
Nat Med, 2017 Mar 28; 23(5). PMID: 28346412    Free PMC article.
Highly Cited.
Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway.
Xin Nie, Shao-Ru Chen, +5 authors, Guo-Chun Zhou.
Sci Rep, 2017 Jul 07; 7(1). PMID: 28680097    Free PMC article.
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response.
Oh Youn Kim, Hyun Taek Park, +5 authors, Yong Song Gho.
Nat Commun, 2017 Sep 22; 8(1). PMID: 28931823    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.
Elizabeth K Duperret, Megan C Wise, +8 authors, David B Weiner.
Mol Ther, 2017 Dec 19; 26(2). PMID: 29249395    Free PMC article.
Informatics for cancer immunotherapy.
J Hammerbacher, A Snyder.
Ann Oncol, 2017 Dec 19; 28(suppl_12). PMID: 29253114    Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
John M Wrangle, Alicia Patterson, +7 authors, Mark P Rubinstein.
J Interferon Cytokine Res, 2018 Feb 15; 38(2). PMID: 29443657    Free PMC article.
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.
Nicolle H Rekers, Veronica Olivo Pimentel, +8 authors, Philippe Lambin.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632732    Free PMC article.
Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade.
Netonia Marshall, Keino Hutchinson, +7 authors, Joshua D Brody.
Cancer Discov, 2019 Aug 04; 9(11). PMID: 31375522    Free PMC article.
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.
Lin Shui, Xi Yang, +3 authors, Hong Zhu.
Front Immunol, 2020 Feb 06; 10. PMID: 32010123    Free PMC article.
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Hongxing Shen, Eddy Shih-Hsin Yang, +4 authors, Lewis Zhichang Shi.
Genes Dis, 2020 Feb 12; 6(3). PMID: 32042863    Free PMC article.
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
Yi Yang, Gang Jin, +7 authors, Zijiang Zhu.
Front Pharmacol, 2020 Mar 03; 11. PMID: 32116716    Free PMC article.
Systematic Review.
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Sara Saab, Hussein Zalzale, +3 authors, Humam Kadara.
Front Immunol, 2020 Mar 03; 11. PMID: 32117295    Free PMC article.
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.
Lionel B Ivashkiv.
Nat Rev Immunol, 2018 Jun 21; 18(9). PMID: 29921905    Free PMC article.
Highly Cited. Review.
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Rachael M Zemek, Wee Loong Chin, +3 authors, W Joost Lesterhuis.
Front Immunol, 2020 Mar 07; 11. PMID: 32133005    Free PMC article.
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Yuji Sato, Jennifer K Bolzenius, +4 authors, Vivek K Arora.
JCI Insight, 2018 Dec 07; 3(23). PMID: 30518683    Free PMC article.
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay, Christophe Caux.
J Immunother Cancer, 2019 Mar 30; 7(1). PMID: 30922400    Free PMC article.
Highly Cited. Review.
Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
Spela Kos, Alessandra Lopes, +6 authors, Gaelle Vandermeulen.
PLoS One, 2019 Jun 01; 14(5). PMID: 31150505    Free PMC article.
Cytokines that target immune killer cells against tumors.
Jian Qiao, Yang-Xin Fu.
Cell Mol Immunol, 2020 Jun 12; 17(7). PMID: 32523115    Free PMC article.
Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells.
Xiufeng Jiang, Hui Wu, +5 authors, Ping Yu.
Cancer Cell Int, 2019 Apr 06; 19. PMID: 30948928    Free PMC article.
Roles of IFN-γ in tumor progression and regression: a review.
Dragica Jorgovanovic, Mengjia Song, Liping Wang, Yi Zhang.
Biomark Res, 2020 Oct 03; 8. PMID: 33005420    Free PMC article.
A Bivalent Recombinant Mycobacterium bovis BCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4+ T Cell Immune Response.
Alex I Kanno, Cibelly Goulart, +2 authors, Ivan P Nascimento.
Biomed Res Int, 2019 Apr 04; 2019. PMID: 30941374    Free PMC article.
Local and Systemic IL-7 Concentration in Gastrointestinal-Tract Cancers.
Iwona Bednarz-Misa, Dorota Diakowska, Małgorzata Krzystek-Korpacka.
Medicina (Kaunas), 2019 Jun 13; 55(6). PMID: 31185636    Free PMC article.
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy.
Nicola Principe, Joel Kidman, +15 authors, Jonathan Chee.
Front Immunol, 2020 Dec 03; 11. PMID: 33262762    Free PMC article.
Novel Combination Therapies for the Treatment of Bladder Cancer.
Mei Peng, Di Xiao, +4 authors, Xiaoping Yang.
Front Oncol, 2021 Feb 16; 10. PMID: 33585182    Free PMC article.
NF-κB in Cancer Immunity: Friend or Foe?
Guilhem Lalle, Julie Twardowski, Yenkel Grinberg-Bleyer.
Cells, 2021 Feb 13; 10(2). PMID: 33572260    Free PMC article.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective.
Adan Rios, Georgina To'a Salazar, Ningyan Zhang, Zhiqiang An.
Antib Ther, 2019 Mar 14; 2(1). PMID: 33928220    Free PMC article.
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Aung Naing, Jeffrey R Infante, +21 authors, Martin Oft.
Cancer Cell, 2018 Nov 14; 34(5). PMID: 30423297    Free PMC article.
Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma.
Asmita Chopra, Ruben Zamora, +10 authors, Amer H Zureikat.
J Immunother, 2021 May 04; 44(5). PMID: 33935273    Free PMC article.
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More.
Yang Li, Wenfang Miao, +4 authors, Shouju Wang.
Front Bioeng Biotechnol, 2021 Jun 22; 9. PMID: 34150736    Free PMC article.
Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer.
Petros X E Mouratidis, Marcia Costa, +2 authors, Gail Ter Haar.
J R Soc Interface, 2021 Jul 08; 18(180). PMID: 34229458    Free PMC article.
Advancing to the era of cancer immunotherapy.
Yun Wang, Min Wang, Hao-Xiang Wu, Rui-Hua Xu.
Cancer Commun (Lond), 2021 Jun 25; 41(9). PMID: 34165252    Free PMC article.
Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.
Sarah C Sasson, Stephanie M Slevin, +24 authors, Oliver Brain.
Gastroenterology, 2021 Jun 21; 161(4). PMID: 34147519    Free PMC article.
Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.
Lewis Zhichang Shi, James A Bonner.
Int J Mol Sci, 2021 Nov 28; 22(22). PMID: 34830176    Free PMC article.
Systematic Review.
Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.
Xuedan He, Shiqi Zhou, +12 authors, Jonathan F Lovell.
J Immunother Cancer, 2021 Dec 05; 9(12). PMID: 34862254    Free PMC article.
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Jiawei Shi, Junwei Liu, +9 authors, Weijia Fang.
J Immunother Cancer, 2022 Feb 02; 10(1). PMID: 35101942    Free PMC article.
Revisiting the melanomagenic pathways and current therapeutic approaches.
Pavan Kumar Dhanyamraju, Solomon Rotimi, Priyanjali Bhattacharya, Trupti N Patel.
Mol Biol Rep, 2022 Apr 11;. PMID: 35397763
Inducible Co-Stimulator ICOS Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma.
Gujie Wu, Min He, +2 authors, Qun Xue.
Int J Gen Med, 2022 Apr 15; 15. PMID: 35418779    Free PMC article.
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.
Francesca Carlino, Anna Diana, +8 authors, Michele Orditura.
Cancers (Basel), 2022 May 15; 14(9). PMID: 35565233    Free PMC article.